m/z
| p-value |
---|
2489.3052 | 0.018082 |
2318.2202 | 0.030239 |
2209.0934 | 0.041789** |
2215.2849 | 0.041789 |
2376.2096 | 0.041789 |
1545.616 | 0.048844 |
- Six peaks were significantly differential comparing NSCLC patients with short progression-free survival and long progression-free survival. All peaks were up-regulated in the group with short progression-free survival. None of the six peaks were positively identified. Ordered by p-value. ** identified by Tempst et al. as high-molecular-weight kininogen [19].